Literature DB >> 28847186

An update on medications and noninvasive brain stimulation to augment language rehabilitation in post-stroke aphasia.

Sadhvi Saxena1, Argye E Hillis1.   

Abstract

INTRODUCTION: Aphasia is among the most debilitating outcomes of stroke. Aphasia is a language disorder occurring in 10-30% of stroke survivors. Speech and Language Therapy (SLT) is the gold standard, mainstay treatment for aphasia, but gains from SLT may be incomplete. Pharmaceutical and noninvasive brain stimulation (NIBS) techniques may augment the effectiveness of SLT. Areas covered: Herein reviewed are studies of the safety and efficacy of these adjunctive interventions for aphasia, including randomized placebo-controlled and open-label trials, as well as case series from Pubmed, using search terms 'pharmacological,' 'tDCS' or 'TMS' combined with 'aphasia' and 'stroke.' Expert commentary: Relatively small studies have included participants with a range of aphasia types and severities, using inconsistent interventions and outcome measures. Results to-date have provided promising, but weak to moderate evidence that medications and/or NIBS can augment the effects of SLT for improving language outcomes. We end with recommendations for future approaches to studying these interventions, with multicenter, double-blind, randomized controlled trials.

Entities:  

Keywords:  Aphasia; SSRI; catecholamines; cholinergic; neuroplasticity; noninvasive brain stimulation; rTMS; stroke; tDCS

Mesh:

Year:  2017        PMID: 28847186     DOI: 10.1080/14737175.2017.1373020

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  10 in total

1.  Frontal aslant tracts as correlates of lexical retrieval in MS.

Authors:  Zafer Keser; Argye E Hillis; Paul E Schulz; Khader M Hasan; Flavia M Nelson
Journal:  Neurol Res       Date:  2020-06-19       Impact factor: 2.448

Review 2.  Developments in treating the nonmotor symptoms of stroke.

Authors:  Argye E Hillis
Journal:  Expert Rev Neurother       Date:  2020-05-12       Impact factor: 4.618

Review 3.  Potential Benefits of Music Therapy on Stroke Rehabilitation.

Authors:  Chengyan Xu; Zixia He; Zhipeng Shen; Fei Huang
Journal:  Oxid Med Cell Longev       Date:  2022-06-15       Impact factor: 7.310

Review 4.  Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke.

Authors:  F Chollet; J Rigal; P Marque; M Barbieux-Guillot; N Raposo; V Fabry; J F Albucher; J Pariente; I Loubinoux
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-23       Impact factor: 5.081

5.  Efficacy of exercise rehabilitation program accompanied by experiential music for recovery of aphasia in single cerebrovascular accidents: a randomized controlled trial.

Authors:  Katerina Aravantinou-Fatorou; George Fotakopoulos
Journal:  Ir J Med Sci       Date:  2020-08-01       Impact factor: 1.568

6.  Diagnosing and managing post-stroke aphasia.

Authors:  Shannon M Sheppard; Rajani Sebastian
Journal:  Expert Rev Neurother       Date:  2020-12-10       Impact factor: 4.618

7.  A Review of Biological Interventions in Chronic Aphasia.

Authors:  E Susan Duncan; Aswathy Anakkathil Pradeep; Steven L Small
Journal:  Ann Indian Acad Neurol       Date:  2020-09-25       Impact factor: 1.383

8.  Low-Frequency vs. Theta Burst Transcranial Magnetic Stimulation for the Treatment of Chronic Non-fluent Aphasia in Stroke: A Proof-of-Concept Study.

Authors:  Ting-Yu Chou; Jia-Chi Wang; Mu-Yun Lin; Po-Yi Tsai
Journal:  Front Aging Neurosci       Date:  2022-01-14       Impact factor: 5.750

9.  Cognitive and Linguistic Benefits of Aerobic Exercise: A State-of-the-Art Systematic Review of the Stroke Literature.

Authors:  Jamie F Mayer; Chaleece W Sandberg; Jennifer Mozeiko; Elizabeth B Madden; Laura L Murray
Journal:  Front Rehabil Sci       Date:  2021-12-24

Review 10.  Tongue Acupuncture for the Treatment of Poststroke Aphasia: A Systematic Review and Meta-Analysis.

Authors:  Shengping Yang; Li Li; Rong Jiang; Haoying Ding; Fei Xu; Lulu Ge; Peng Kuang; Zuhong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-03       Impact factor: 2.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.